In a Phase 3 trial the US drugmaker reported that, among obese people tirzepatide reduces the risk of heart failure by 38 per cent and reduces risk of hospitalization for heart failure by 56 per cent. Read more: https://pharma.economictimes.indiatimes.com/news/research-and-development/eli-lillys-tirzepatide-cuts-heart-failure-risk-by-38-and-halves-hospitalizations/121750039